Overview

The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Status:
Completed

Trial end date:
1996-01-01

Target enrollment:

Participant gender:

Summary

To compare the effects on CD4 counts and safety of MK-639 (indinavir, IDV) and AZT administered concomitantly to MK-639 alone and AZT alone in HIV-1 seropositive patients.

Phase:

N/A

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Indinavir
Zidovudine